West Virginia HB5442 mandates training for healthcare providers on the uses and indications of progesterone and mifepristone for pregnant women.

West Virginia HB5442 requires hospitals and similar institutions to ensure their licensed healthcare providers complete training on the uses and indications of progesterone and mifepristone for pregnant women. The Office of Maternal, Child and Family Health will develop this training in consultation with an advisory council, focusing on scientific literature about the risks and treatment of adverse outcomes from chemical abortions. Hospitals providing gynecologic, obstetric, or emergency care must ensure their staff complete this training.

West Virginia HB5442 mandates training for healthcare providers on the uses and indications of progesterone and mifepristone for pregnant women.

West Virginia HB5442 requires hospitals and similar institutions to ensure their licensed healthcare providers complete training on the uses and indications of progesterone and mifepristone for pregnant women. The Office of Maternal, Child and Family Health will develop this training in consultation with an advisory council, focusing on scientific literature about the risks and treatment of adverse outcomes from chemical abortions. Hospitals providing gynecologic, obstetric, or emergency care must ensure their staff complete this training.